FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892184938> ?p ?o ?g. }

• W2892184938 endingPage "222" @default.
• W2892184938 startingPage "213" @default.
• W2892184938 abstract "Background: Cancer is one of the most common life-threatening diseases worldwide; many patients develop multidrug resistance after treatment with anticancer drugs. The main mechanism leading to multidrug resistance is the overexpression of ABC transporters in cancer cells. Chemosensitizers are needed to inhibit the activity of ABC transporters, resulting in higer intracellular concentration of anticancer drugs. Some secondary metabolites have been reported to be chemosensitizers by inhibiting ABC transporters. Epigallocatechin gallate (EGCG), tannic acid, and curcumin were employed in this study. Different assays were used to detect whether they have the ability to inhibit P-gp activity and overcome multidrug resistance in cancer cells overexpressing P-gp. Hypothesis/Purpose: CEM/ADR 5000 and Caco-2 cell lines, which overexpress P-gp, are multidrug resistant cell lines. We first detected whether the combination of polyphenols (EGCG, tannic acid, curcumin) and doxorubicin, an anticancer drug, is synergistic or not. To further understand the potential mechanism, EGCG, tannic acid, and curcumin were tested to check whether they have the ability to inhibit P-gp activity. When P-gp activity is inhibited, the intracellular concentration of doxorubicin is higher, resulting in enhanced cytotoxicity of doxorubicin. Study design: The P-gp overexpressing human colon cancer cell line Caco-2 and human T-lymphoblastic leukemia cell line CEM/ADR 5000 were used in this study. Two-drug combinations (doxorubicin + polyphenol) and three-drug combinations (doxorubicin + polyphenol + digitonin) were tested to examine potential synergism. The potential mechanism leading to synergism would be the inhibition of P-gp activity. A Rhodamine 123 assay and Calcein-AM assay in Caco-2 and CEM/ADR 5000, respectively, were used to detect P-gp inhibition by EGCG, curcumin, and tannic acid. Methods: MTT assay was used to determine the cytotoxicity of doxorubicin, polyphenols and digitonin alone, and then their combinations. Furthermore, Rhodamine 123 and Calcein-AM were used to detect the effects of polyphenols on the activity of P-gp. Results: The results demonstrated that a combination of non-toxic concentrations of each polyphenol with doxorubicin synergistically sensitized Caco-2 and CEM/ADR 5000 cells. Furthermore, three-drug combinations (doxorubicin + polyphenol + digitonin) were much more effective. In addition, the activity of P-gp in Caco-2 and CEM/ADR 5000 cells was measured. Consistent with the combination results, tannic acid and curcumin decreased the activity of P-gp both in Caco-2 and CEM/ADR 5000. EGCG, which weakly affected the activity of P-gp in CEM/ADR 5000, only had an effect on P-gp under higher concentration in Caco-2 cells. Conclusion: Our results show that EGCG, curcumin, and tannic acid, when combined with doxorubicin, can exert synergism, mediated by a reduced activity of P-gp. This study suggests that polyphenols, by modulating the activity of P-gp, may be used as chemosensitisers." @default.
• W2892184938 created "2018-09-27" @default.
• W2892184938 creator A5011704720 @default.
• W2892184938 creator A5034011528 @default.
• W2892184938 creator A5050570163 @default.
• W2892184938 date "2018-11-01" @default.
• W2892184938 modified "2023-10-11" @default.
• W2892184938 title "Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin" @default.
• W2892184938 cites W1481361569 @default.
• W2892184938 cites W1505612226 @default.
• W2892184938 cites W1553345136 @default.
• W2892184938 cites W175263069 @default.
• W2892184938 cites W1852359153 @default.
• W2892184938 cites W1911849142 @default.
• W2892184938 cites W1966303307 @default.
• W2892184938 cites W1970487125 @default.
• W2892184938 cites W1981140460 @default.
• W2892184938 cites W1991327193 @default.
• W2892184938 cites W1993598475 @default.
• W2892184938 cites W2001809290 @default.
• W2892184938 cites W2010183849 @default.
• W2892184938 cites W2017201518 @default.
• W2892184938 cites W2022455504 @default.
• W2892184938 cites W2030594068 @default.
• W2892184938 cites W2045222833 @default.
• W2892184938 cites W2055904567 @default.
• W2892184938 cites W2066621807 @default.
• W2892184938 cites W2079810866 @default.
• W2892184938 cites W2087266891 @default.
• W2892184938 cites W2094924740 @default.
• W2892184938 cites W2103562758 @default.
• W2892184938 cites W2105697161 @default.
• W2892184938 cites W2114918609 @default.
• W2892184938 cites W2122351832 @default.
• W2892184938 cites W2134795955 @default.
• W2892184938 cites W2305064809 @default.
• W2892184938 cites W2555874130 @default.
• W2892184938 cites W2949407848 @default.
• W2892184938 doi "https://doi.org/10.1016/j.phymed.2018.09.169" @default.
• W2892184938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30466981" @default.
• W2892184938 hasPublicationYear "2018" @default.
• W2892184938 type Work @default.
• W2892184938 sameAs 2892184938 @default.
• W2892184938 citedByCount "51" @default.
• W2892184938 countsByYear W28921849382019 @default.
• W2892184938 countsByYear W28921849382020 @default.
• W2892184938 countsByYear W28921849382021 @default.
• W2892184938 countsByYear W28921849382022 @default.
• W2892184938 countsByYear W28921849382023 @default.
• W2892184938 crossrefType "journal-article" @default.
• W2892184938 hasAuthorship W2892184938A5011704720 @default.
• W2892184938 hasAuthorship W2892184938A5034011528 @default.
• W2892184938 hasAuthorship W2892184938A5050570163 @default.
• W2892184938 hasConcept C109316439 @default.
• W2892184938 hasConcept C121608353 @default.
• W2892184938 hasConcept C133936738 @default.
• W2892184938 hasConcept C178790620 @default.
• W2892184938 hasConcept C185592680 @default.
• W2892184938 hasConcept C202751555 @default.
• W2892184938 hasConcept C2776694085 @default.
• W2892184938 hasConcept C2778250585 @default.
• W2892184938 hasConcept C2781303535 @default.
• W2892184938 hasConcept C2781393965 @default.
• W2892184938 hasConcept C501593827 @default.
• W2892184938 hasConcept C54355233 @default.
• W2892184938 hasConcept C55493867 @default.
• W2892184938 hasConcept C86803240 @default.
• W2892184938 hasConcept C96232424 @default.
• W2892184938 hasConcept C98274493 @default.
• W2892184938 hasConceptScore W2892184938C109316439 @default.
• W2892184938 hasConceptScore W2892184938C121608353 @default.
• W2892184938 hasConceptScore W2892184938C133936738 @default.
• W2892184938 hasConceptScore W2892184938C178790620 @default.
• W2892184938 hasConceptScore W2892184938C185592680 @default.
• W2892184938 hasConceptScore W2892184938C202751555 @default.
• W2892184938 hasConceptScore W2892184938C2776694085 @default.
• W2892184938 hasConceptScore W2892184938C2778250585 @default.
• W2892184938 hasConceptScore W2892184938C2781303535 @default.
• W2892184938 hasConceptScore W2892184938C2781393965 @default.
• W2892184938 hasConceptScore W2892184938C501593827 @default.
• W2892184938 hasConceptScore W2892184938C54355233 @default.
• W2892184938 hasConceptScore W2892184938C55493867 @default.
• W2892184938 hasConceptScore W2892184938C86803240 @default.
• W2892184938 hasConceptScore W2892184938C96232424 @default.
• W2892184938 hasConceptScore W2892184938C98274493 @default.
• W2892184938 hasLocation W28921849381 @default.
• W2892184938 hasLocation W28921849382 @default.
• W2892184938 hasOpenAccess W2892184938 @default.
• W2892184938 hasPrimaryLocation W28921849381 @default.
• W2892184938 hasRelatedWork W18137048 @default.
• W2892184938 hasRelatedWork W1992470912 @default.
• W2892184938 hasRelatedWork W199875588 @default.
• W2892184938 hasRelatedWork W2040835855 @default.
• W2892184938 hasRelatedWork W2063250955 @default.
• W2892184938 hasRelatedWork W2065723669 @default.
• W2892184938 hasRelatedWork W2374053201 @default.
• W2892184938 hasRelatedWork W2922415798 @default.
• W2892184938 hasRelatedWork W4210691215 @default.

• next